PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
Manuscript NO: 76264
Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05429043
Position: Editorial Board
Academic degree: PhD
Professional title: Assistant Professor
Reviewer’s Country/Territory: India
Author’s Country/Territory: Greece
Manuscript submission date: 2022-03-09
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-03-11 08:53
Reviewer performed review: 2022-03-11 10:45
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes [ ] No</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The article is very interesting, but I have a few concerns. 1. The title should be specific for oncologic malignancies. It is better to mention separately pre-clinical evidence and clinical evidence for each type of formulation. The abstract can be included with details of type of formulation mentioned in the content. The graphical extract will be helpful for understanding the content. Not found any details on liver cancer based formulation in the table or content?
Name of journal: World Journal of Clinical Oncology

Manuscript NO: 76264

Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06275113

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Greece

Manuscript submission date: 2022-03-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-11 02:09

Reviewer performed review: 2022-03-21 07:48

Review time: 10 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

<p>| Re-review | [ ] Yes | [ ] No |</p>
<table>
<thead>
<tr>
<th>Peer-reviewer statements</th>
<th>Peer-Review: [Y] Anonymous  [ ] Onymous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conflicts-of-Interest:</td>
<td>[ ] Yes  [Y] No</td>
</tr>
</tbody>
</table>

**SPECIFIC COMMENTS TO AUTHORS**

Overall the article lack a main logistic flow. The title clearly state “nanomedicine”, but a considerable portion of the article describes immunotherapy and checkpoint blockade therapy, give an impression of lack of focus. The entire immune checkpoint inhibitor section appeared had no relevance with nanomedicine. The NK cell section included CAR-T therapy, which seems mixed content. At least, the concept of nanomedicine needs a clear definition in the beginning. Introduction section, first paragraph, the last sentence, “ultimately hindering the cell cycle”, hindering cell cycle? Please explain.
Name of journal: World Journal of Clinical Oncology

Manuscript NO: 76264

Title: Nanomedicine approaches for the treatment of hematologic and oncologic malignancies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05429043

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer’s Country/Territory: India

Author’s Country/Territory: Greece

Manuscript submission date: 2022-03-09

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2022-06-07 05:29

Reviewer performed review: 2022-06-07 06:44

Review time: 1 Hour

Scientific quality

[ ] Grade A: Excellent  [ ] Grade B: Very good  [ ] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish

Language quality

[ ] Grade A: Priority publishing  [ ] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

Conclusion

[ ] Accept (High priority)  [ ] Accept (General priority)
[ ] Minor revision  [ ] Major revision  [ ] Rejection

Peer-reviewer

Peer-Review: [ ] Anonymous  [ ] Onymous
SPECIFIC COMMENTS TO AUTHORS

Please upload the figures. Now the file uploaded is manuscript file.